Premium
Lixisenatide (Lyxumia): new GLP‐1 mimetic for type 2 diabetes
Author(s) -
Chaplin Steve
Publication year - 2014
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1177
Subject(s) - lixisenatide , medicine , type 2 diabetes , adverse effect , diabetes mellitus , pharmacology , endocrinology , exenatide
Lixisenatide is a new GLP‐1 mimetic for use in type 2 diabetes with oral agents and/or insulin. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Dr Frank Joseph discusses its place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom